Skip to main content
Premium Trial:

Request an Annual Quote

Olink Acquires IP from In Situ RCP

NEW YORK (GenomeWeb News) – Olink Bioscience said today that it has acquired a family of patents from the Danish firm In Situ RCP that it plans to use in its nucleic acid amplification and protein analysis applications.

The Uppsala, Sweden-based company said the three patents are related to target primed rolling circle amplification and amplifying circular molecules.

Olink's product line is based on its proximity ligation assay technology, which uses dual recognition of analytes and a DNA amplification reporter system.

"The acquisition of these patents is an important step in the process to further strengthen our already strong position within the field of DNA-based immunoassays, as well as to allow us to expand into novel areas of nucleic acid based analysis based on rolling circle amplification," Mats Gullberg, CTO of Olink, said in a statement.

Financial terms of the agreement were not released.